Efficacy and Safety of DA5221-T When Added to Ongoing DA5221-B1 and DA5221-B2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control - Trial NCT06290349
Access comprehensive clinical trial information for NCT06290349 through Pure Global AI's free database. This Phase 3 trial is sponsored by Dong-A ST Co., Ltd. and is currently Not yet recruiting. The study focuses on Type 2 Diabetes. Target enrollment is 162 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Dong-A ST Co., Ltd.
Timeline & Enrollment
Phase 3
Feb 28, 2024
Nov 30, 2025
Primary Outcome
Change from the baseline in HbA1c (%) after 24 weeks
Summary
This study evaluates the efficacy and safety of adding the SGLT-2 inhibitor DA5221-T to the
 combination therapy of DA5221-B1 and the DPP-4 inhibitor DA5221-B2 in patients with type 2
 diabetes who have inadequate blood glucose control. The study focuses on assessing the
 effectiveness and safety of the triple combination therapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06290349
Non-Device Trial